A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
JERUSALEM, Feb. 04, 2025 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), a pioneer in AI-powered orthodontic solutions, today announced a strategic partnership with Aran Research & Development, a premier Israel-based medical device developer...
SINGAPORE, Jan. 31, 2025 /PRNewswire/ -- Hotel101 Global Pte. Ltd ("Hotel101" or "HBNB"), an asset-light, prop-tech hospitality platform business designed for rapid global growth, and JVSPAC Acquisition Corp. (NASDAQ: JVSA) ("JVSPAC"), a special purpose acquisition...
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025...
JERUSALEM, Dec. 04, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a...
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have...
JERUSALEM, Nov. 19, 2024 -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), an AI-based orthodontic platform company, has developed ZSmile, an innovative solution that corrects smiles by straightening teeth, using pulsating air delivered through a...
The gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology's new supplement LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine...
National rollout provides enhanced accessibility to Niagen IV, a significant advancement in NAD+ IV therapy LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today...
Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 LOS ANGELES - ChromaDex Corp....
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it has rescheduled its previously announced conference call to Thursday, October 31, 2024 at 4:30 p.m....